Nursing Review Issue 4 Jul-Aug 2019 | Page 31

workforce It’s probably helping their bottom line more than anything else. Yes, I think so. And because it is industry regulated, it can be subject to erosion or strengthening more easily. But something we are concerned about is the erosion that can occur. This code is also under the view of the ACCC. So they do have some say, but they don’t intervene a great deal. Would physical payments to any health professional ever happen, where a pharmaceutical company would literally write a cheque for X amount of dollars? I can’t really comment. It would not surprise me, and anecdotally I have heard that these occur. But I don’t have any data to draw upon. Going back to non-prescribing clinicians. If pharmaceuticals are giving these ‘gifts’, or helping them in these ways, is there an ethical issue there? It’s a complex one. We’ve got to take into account the fact that nurses can really benefit the pharmaceutical industry – and this is a good thing, because they make our medicines. It’s good to have a nurse, say, on the advisory committee, or giving insights to the pharmaceutical industry on the medicines that patients are using or how they’re dealing with it, and so forth. But we can’t overlook the fact there is a danger as well, that these payments would subconsciously or otherwise influence the sort of practice of the nurse who is receiving them. Or they could influence their colleagues to bias their clinical care in a way that benefits the pharmaceutical company. We have to remember that a lot of what the company is doing is marketing strategy. And we can see that, with doctors, it’s highly effective. characteristics of the highest paid people that those companies are sponsoring. It stands to reason that if you influence a doctor, they will more likely prescribe this medication. But how does a non- prescribing nurse influence a doctor? In Australia we have quite good records, although they’re not very accessible. I think we could improve our capture. So, for example, we only capture 35 pharmaceutical companies out of all the companies in Australia. We don’t capture medical device companies, which we know are doing a lot of marketing. In the scheme of the world, we’re doing quite well because we’re capturing these non-prescribing healthcare professionals, which most aren’t. However, we aren’t capturing a lot of the types of exposure to Something interesting coming out of the data are the areas being targeted in terms of the non-prescribing healthcare professionals. We’re seeing people targeted with roles in chronic disease and areas that may require high adherence to medicines. These are areas in which nurses are encouraged to play quite a big role. Nurses often have roles on formulary committees. They can influence or recommend things the prescriber might use, and they also become very close, I suppose, to the patient. They are a highly trusted source that can influence the sorts of medicines the patient might want. So I think nurses and other non-prescribers can really influence multiple points of the chain, from purchasing the product, to influencing the prescriber, to influencing the patient. I’m not using ‘influencing’ in a bad way there. But they have, I think, a lot more influence than we sometimes give them credit for. What were the methods you used to find and make sense of this data? We got publicly available reports from Medicines Australia. Thirty-five large pharmaceutical companies who are members of that organisation submit reports to them every six months. This is where we obtained the data. We then tried to identify unique people. Sometimes that was a bit challenging, because their names might be presented differently and so forth. Then we did a descriptive analysis using what was in that data to pull out the types of payments that people are getting, the types of companies that are sponsoring non-prescribers, how much different people might be getting. Then we also did a little bit of a dig, almost like taking some case studies and looking at which of the companies are paying the most to these non-prescribing healthcare professionals, and what are the Did you have any engagement with any of these healthcare professionals? No, we didn’t contact anyone. Do you feel there needs to be more transparency on who’s being paid what in the healthcare profession? Nurses can influence multiple points of the chain, from purchasing the product, to influencing the prescriber and the patient. industry that people get. These payments are really a very small part of exposure to industry. Do you see your study having an effect on the way non-prescribing clinicians will accept payments? I think that, more than necessarily having an effect on whether individuals accept payments – although that would be beneficial – what I really like about our study is that it shows that the pharmaceutical industry isn’t ignoring non‑prescribing healthcare professionals. We’ve been a bit dismissive, I think, of their importance. There’s therefore an idea that payments or any kind of pharmaceutical industry interaction with non-prescribing healthcare professionals is sort of irrelevant. Our study shows the industry doesn’t think it’s irrelevant. Perhaps we need to think about whether our non-prescribing or non-medical, non-doctor healthcare professionals are well equipped to evaluate, understand the risks of, and know how to deal with the industry interactions they face day to day. ■ nursingreview.com.au | 29